Free Trial

Vor Biopharma (VOR) Competitors

Vor Biopharma logo
$31.28 +3.35 (+11.99%)
Closing price 09/23/2025 04:00 PM Eastern
Extended Trading
$32.85 +1.58 (+5.04%)
As of 09:16 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

VOR vs. AVXL, IMNM, AVBP, PRAX, GOSS, AKBA, VALN, NAGE, SANA, and OCS

Should you be buying Vor Biopharma stock or one of its competitors? The main competitors of Vor Biopharma include Anavex Life Sciences (AVXL), Immunome (IMNM), ArriVent BioPharma (AVBP), Praxis Precision Medicines (PRAX), Gossamer Bio (GOSS), Akebia Therapeutics (AKBA), Valneva (VALN), Niagen Bioscience (NAGE), Sana Biotechnology (SANA), and Oculis (OCS). These companies are all part of the "pharmaceutical products" industry.

Vor Biopharma vs. Its Competitors

Anavex Life Sciences (NASDAQ:AVXL) and Vor Biopharma (NYSE:VOR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation.

Vor Biopharma's return on equity of 0.00% beat Anavex Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Anavex Life SciencesN/A -45.67% -40.21%
Vor Biopharma N/A N/A N/A

Anavex Life Sciences has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Comparatively, Vor Biopharma has a beta of 2.05, meaning that its share price is 105% more volatile than the S&P 500.

31.6% of Anavex Life Sciences shares are owned by institutional investors. Comparatively, 97.3% of Vor Biopharma shares are owned by institutional investors. 11.0% of Anavex Life Sciences shares are owned by insiders. Comparatively, 0.5% of Vor Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Anavex Life Sciences currently has a consensus price target of $44.00, indicating a potential upside of 417.04%. Vor Biopharma has a consensus price target of $113.83, indicating a potential upside of 263.92%. Given Anavex Life Sciences' stronger consensus rating and higher possible upside, research analysts clearly believe Anavex Life Sciences is more favorable than Vor Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Anavex Life Sciences
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Vor Biopharma
0 Sell rating(s)
4 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.56

Anavex Life Sciences is trading at a lower price-to-earnings ratio than Vor Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Anavex Life SciencesN/AN/A-$43M-$0.57-14.93
Vor BiopharmaN/AN/AN/A-$273.20-0.11

In the previous week, Vor Biopharma had 17 more articles in the media than Anavex Life Sciences. MarketBeat recorded 18 mentions for Vor Biopharma and 1 mentions for Anavex Life Sciences. Anavex Life Sciences' average media sentiment score of 1.47 beat Vor Biopharma's score of 0.33 indicating that Anavex Life Sciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Anavex Life Sciences
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Vor Biopharma
3 Very Positive mention(s)
1 Positive mention(s)
10 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Anavex Life Sciences and Vor Biopharma tied by winning 6 of the 12 factors compared between the two stocks.

Get Vor Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for VOR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VOR vs. The Competition

MetricVor BiopharmaBiological Products, Except Diagnostic Substances IndustryMedical SectorNYSE Exchange
Market Cap$198.13M$241.80M$5.76B$21.71B
Dividend YieldN/AN/A5.53%3.52%
P/E Ratio-18.96N/A76.2529.84
Price / SalesN/A305.26470.4960.74
Price / CashN/AN/A37.4624.72
Price / BookN/A2.8913.354.59
Net IncomeN/A-$111.70M$3.29B$1.00B
7 Day Performance2.89%6.24%1.83%0.64%
1 Month Performance-27.93%-35.53%3.98%2.77%
1 Year Performance103.14%103.14%74.39%14.49%

Vor Biopharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VOR
Vor Biopharma
2.7451 of 5 stars
$31.28
+12.0%
$113.83
+263.9%
+88.4%$198.13MN/A-18.96140Analyst Upgrade
Gap Down
AVXL
Anavex Life Sciences
3.8442 of 5 stars
$9.09
-3.0%
$44.00
+384.0%
+55.0%$804.83MN/A-15.9540
IMNM
Immunome
2.1647 of 5 stars
$9.48
+2.9%
$22.89
+141.4%
-24.6%$801.68M$9.04M-3.0840News Coverage
Analyst Forecast
AVBP
ArriVent BioPharma
1.7424 of 5 stars
$18.95
-3.9%
$39.14
+106.6%
-19.3%$799.61MN/A0.0040
PRAX
Praxis Precision Medicines
2.4264 of 5 stars
$40.45
+7.3%
$85.88
+112.3%
-14.1%$793.67M$8.55M-3.29110
GOSS
Gossamer Bio
3.9446 of 5 stars
$3.18
-8.1%
$8.50
+167.3%
+208.0%$786.74M$114.70M-5.13180Analyst Downgrade
AKBA
Akebia Therapeutics
3.8232 of 5 stars
$2.92
-1.0%
$6.75
+131.2%
+116.0%$782.18M$160.18M-17.18430Positive News
VALN
Valneva
2.649 of 5 stars
$8.93
-0.1%
$15.00
+68.0%
+69.7%$768.19M$183.52M-9.11700
NAGE
Niagen Bioscience
1.594 of 5 stars
$9.68
+0.7%
$13.42
+38.6%
N/A$766.43M$99.60M73.92120
SANA
Sana Biotechnology
3.1362 of 5 stars
$3.23
+0.3%
$8.00
+147.7%
-20.3%$765.74MN/A-3.05380Positive News
Analyst Forecast
OCS
Oculis
2.9154 of 5 stars
$17.33
-0.4%
$35.75
+106.3%
+48.5%$759.73M$780K0.002Analyst Downgrade

Related Companies and Tools


This page (NYSE:VOR) was last updated on 9/24/2025 by MarketBeat.com Staff
From Our Partners